Patient treatments commence with Clarity’s copper-64/copper-67 SARTATE in neuroblastoma clinical trial
Sydney, Australia 3 November 2020 – Clarity Pharmaceuticals, a clinical stage radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that treatment has commenced in a 64/67Cu-SARTATETM theranostic trial of paediatric patients with neuroblastoma at Memorial Sloan Kettering Cancer Center (MSK) in New York City. The first patient was treated with…